Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imiquimod intravesicular - UroGen Pharma

Next Previous
Drug Profile

Imiquimod intravesicular - UroGen Pharma

Alternative Names: TMX-101; UGN 201; Vesimune

Latest Information Update: 24 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Telormedix
  • Developer UroGen Pharma
  • Class Adjuvants; Aminoquinolines; Antineoplastics; Antivirals; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bladder cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Bladder cancer

Most Recent Events

  • 24 Apr 2026 Phase-I development is ongoing in Bladder-cancer(Combination therapy, Recurrent) in Italy, Spain and USA (Intravesicular, Liquid) (NCT05375903)
  • 09 Jan 2026 UroGen Pharma completes the Phase-I clinical trial in Bladder-cancer (Combination therapy, Recurrent) in Italy, Spain and USA (Intravesicular, Liquid) (NCT05375903)
  • 28 Jul 2025 No recent reports of development identified for phase-I development in Bladder-cancer(Combination therapy, Recurrent) in Italy (Intravesicular, Liquid)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top